David B. Donner, PhD

David B. Donner, PhD

Professor in Residence, Department of Surgery, UCSSF


Phone: (415) 353-9289 (voice)
Box 1932, UCSF
San Francisco, CA 94143-1932

View on UCSF Profiles

Cancer Center Membership

Associate Member » Prostate Cancer» Cancer, Immunity, and Microenvironment


Queens College, New York, NY, B.A., 1966, Chemistry
Rensselaer Polytechnic Institute, New York, NY, Ph.D., 1972, Chemistry
Cornell University, Ithaca, NY, post-doc, 1972-1973, Biochemistry

Professional Experience

  • 2005-present
    Professor in Residence, Department of Surgery, University of California, San Francisco, CA
  • 10/2004-
    Member, Editorial Advisory Board, The Biochemical Journal
  • 2004
    Member Cellular and Molecular Pathology Study Section, NIH
  • 1997-2005
    Professor, Microbiology & Immunology, Indiana Univ. School of Medicine (IUSM)
  • 1993-
    Member, Indiana University Cancer Center (IUSM)
  • 1992-
    Member, Walther Oncology Center (IUSM)
  • 1992-1997
    Professor, Dept. Physiology & Biophysics (IUSM)
  • 1986-1990
    Editor, Endocrinology (journal)
  • 1983-1992
    Associate Member, Memorial Sloan-Kettering Cancer Center (MSKCC), NY, NY Associate Professor, Dept. Cell Biology & Genetics, Cornell Univ. Graduate School of Medical Sciences (CUMC), NY, NY
  • 1983-1990
    Graduate Program Director, Cell Biol. & Genetics, CUMC.
  • 1978-1983
    Assistant Member, MSKCC, Assistant Professor, Dept. Biochemistry, CUMC
  • l973-1978
    Research Associate, MSKCC and Instructor, Dept. Biochemistry, CUMC

Honors & Awards

  • 7/82 to 6/87
    NIH Career Development Award
  • 1/82 to 6/82
    American Cancer Society Faculty Research Award
  • 1984
    Louise & Alston Boyer Young Investigator Award for Laboratory Research
  • 1978-79
    American Diabetes Association Research and Development Award
  • 1962-1966
    NY State Regents Scholarship
  • 1962-1966
    NY State Scholar Incentive Award

Selected Publications

  1. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015 Jun; 17(6):804-15.
    View on PubMed
  2. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One. 2013; 8(9):e73817.
    View on PubMed
  3. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
    View on PubMed
  4. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600.
    View on PubMed
  5. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab. 2012 Apr; 97(4):E637-41.
    View on PubMed
  6. Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-?B activity. Surgery. 2011 Dec; 150(6):1295-302.
    View on PubMed
  7. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011 May 20; 286(20):17543-59.
    View on PubMed
  8. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab. 2011 Mar; 96(3):E554-65.
    View on PubMed
  9. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010 Sep; 8(9):1217-26.
    View on PubMed
  10. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51.
    View on PubMed
  11. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91.
    View on PubMed
  12. Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery. 2009 Dec; 146(6):1208-14.
    View on PubMed
  13. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res. 2009 Oct; 7(10):1655-62.
    View on PubMed
  14. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem. 2009 Jun 5; 284(23):15390-9.
    View on PubMed
  15. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol. 2009 Jul; 16(7):2018-27.
    View on PubMed
  16. Sall2 is a novel p75NTR-interacting protein that links NGF signalling to cell cycle progression and neurite outgrowth. EMBO J. 2009 Feb 4; 28(3):261-73.
    View on PubMed
  17. Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun. 2009 Feb 6; 379(2):626-31.
    View on PubMed
  18. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery. 2008 Dec; 144(6):908-13; discussion 913-4.
    View on PubMed
  19. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer. 2009 Mar; 16(1):267-79.
    View on PubMed
  20. The Sall2 transcription factor is a novel p75NTR binding protein that promotes the development and function of neurons. Ann N Y Acad Sci. 2008 Nov; 1144:53-5.
    View on PubMed

Go to UCSF Profiles, powered by CTSI